Form I Rubisco is one of the most abundant enzymes on Earth. It is responsible for assimilating atmospheric CO2 into organic matter, but how it obtained its high CO2 specificity is unknown.
Due to its precise genome editing capabilities, the prokaryotic CRISPR–Cas system has revolutionized molecular biology – and has potential applications in gene therapy and biotechnology [1]. Nonetheless, recent research has highlighted the need for more compact CRISPR-Cas complexes, which could be delivered to cellular systems more efficiently [2]
The importance of effective adeno-associated virus (AAV) analysis – and how mass photometry can support this – has been recognized in recent publications.
There is no better measure for the success of an analytical technology than its widespread adoption by the people who need the best data! As news of the capabilities and applications of mass photometry spreads, more and more scientists are choosing to use it. In fact, the number of scientific publications relying on mass photometry has grown by an average of 168% per year over the past 6 years. In August 2024, we hit a new milestone: 500 mass photometry papers! For a technology as young as mass photometry, that is truly remarkable.
Refeyn has taken another step to assure mass photometry is a simpler, more efficient bioanalytics tool with the release of a powerful expansion of its consumables portfolio.
Refeyn has established a new Scientific Advisory Board, chaired by Justin Benesch, Professor of Biophysical Chemistry, Oxford University and co-founder of Refeyn. To recognize and help realize the full potential of mass photometry’s unique bioanalytical workflow capabilities, the new board includes external scientific experts in pharmaceutical and biologics discovery, process development and manufacture.
